Hafner FT - Search Results

1

A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay.

Zhao M, Rudek MA, He P, Hafner FT, Radtke M, Wright JJ, Smith BD, Messersmith WA, Hidalgo M, Baker SD. Zhao M, et al. Among authors: hafner ft. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Feb 1;846(1-2):1-7. doi: 10.1016/j.jchromb.2006.06.005. Epub 2006 Jun 23. J Chromatogr B Analyt Technol Biomed Life Sci. 2007. PMID: 16798122

2

Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.

Gerisch M, Hafner FT, Lang D, Radtke M, Diefenbach K, Cleton A, Lettieri J. Gerisch M, et al. Among authors: hafner ft. Cancer Chemother Pharmacol. 2018 Jan;81(1):195-206. doi: 10.1007/s00280-017-3480-9. Epub 2017 Nov 29. Cancer Chemother Pharmacol. 2018. PMID: 29188322 Free PMC article. Clinical Trial.

3

Determination of regorafenib (BAY 73-4506) and its major human metabolites BAY 75-7495 (M-2) and BAY 81-8752 (M-5) in human plasma by stable-isotope dilution liquid chromatography-tandem mass spectrometry.

Hafner FT, Werner D, Kaiser M. Hafner FT, et al. Bioanalysis. 2014;6(14):1923-37. doi: 10.4155/bio.14.52. Bioanalysis. 2014. PMID: 25158964

4

Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models.

Zopf D, Fichtner I, Bhargava A, Steinke W, Thierauch KH, Diefenbach K, Wilhelm S, Hafner FT, Gerisch M. Zopf D, et al. Among authors: hafner ft. Cancer Med. 2016 Nov;5(11):3176-3185. doi: 10.1002/cam4.883. Epub 2016 Oct 13. Cancer Med. 2016. PMID: 27734608 Free PMC article.

5

Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling.

Weber O, Willmann S, Bischoff H, Li V, Vakalopoulos A, Lustig K, Hafner FT, Heinig R, Schmeck C, Buehner K. Weber O, et al. Among authors: hafner ft. Br J Clin Pharmacol. 2012 Feb;73(2):219-31. doi: 10.1111/j.1365-2125.2011.04064.x. Br J Clin Pharmacol. 2012. PMID: 21762205 Free PMC article.

6

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma.

Kissel M, Berndt S, Fiebig L, Kling S, Ji Q, Gu Q, Lang T, Hafner FT, Teufel M, Zopf D. Kissel M, et al. Among authors: hafner ft. Oncotarget. 2017 Nov 6;8(63):107096-107108. doi: 10.18632/oncotarget.22334. eCollection 2017 Dec 5. Oncotarget. 2017. PMID: 29291014 Free PMC article.

7

Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women .

Schultze-Mosgau MH, Schuett B, Hafner FT, Zollmann F, Kaiser A, Hoechel J, Rohde B. Schultze-Mosgau MH, et al. Among authors: hafner ft. Int J Clin Pharmacol Ther. 2017 Jan;55(1):16-24. doi: 10.5414/CP202756. Int J Clin Pharmacol Ther. 2017. PMID: 27841155 Clinical Trial.

8

Dibenzodioxocinones--a new class of CETP inhibitors.

Brückner D, Hafner FT, Li V, Schmeck C, Telser J, Vakalopoulos A, Wirtz G. Brückner D, et al. Among authors: hafner ft. Bioorg Med Chem Lett. 2005 Aug 1;15(15):3611-4. doi: 10.1016/j.bmcl.2005.05.073. Bioorg Med Chem Lett. 2005. PMID: 15975789

9

Noncompetitive immunoassay of small analytes at the femtomolar level by affinity probe capillary electrophoresis: direct analysis of digoxin using a uniform-labeled scFv immunoreagent.

Hafner FT, Kautz RA, Iverson BL, Tim RC, Karger BL. Hafner FT, et al. Anal Chem. 2000 Dec 1;72(23):5779-86. doi: 10.1021/ac000853+. Anal Chem. 2000. PMID: 11128936

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters